Paragon 28 Launches R3ACT™ Stabilization System for Ankle Injuries

Rhea-AI Summary

Paragon 28, Inc. (NYSE: FNA) has launched the R3ACT™ Stabilization System, aimed at enhancing soft tissue healing for syndesmotic ankle injuries. This system is designed to address the complexities of stabilization throughout various healing phases. CEO Albert DaCosta emphasized that around 20% of ankle injuries necessitate implants for recovery, positioning the R3ACT™ as a valuable addition to their ankle fracture solutions. Paragon 28 specializes in the foot and ankle orthopedic market, focusing on innovative solutions to improve patient outcomes.

Positive

• Launch of R3ACT™ Stabilization System addressing syndesmotic injuries.
• CEO highlights importance of product for 20% of ankle injuries requiring implants.
• Enhances company's existing ankle fracture portfolio.

Negative

• None.

ENGLEWOOD, Colo.--(BUSINESS WIRE)-- Paragon 28, Inc. (NYSE: FNA), a leading medical device company exclusively focused on the foot and ankle orthopedic market, announced today the launch of its R3ACT™ Stabilization System, designed to be a simple solution that allows for multi-stage soft tissue healing following an acute or chronic syndesmotic injury to the ankle.

R3ACT™ Stabilization System (Graphic: Business Wire)

Paragon 28’s CEO, Albert DaCosta commented, “Since the inception of Paragon 28, the development of a syndesmotic stabilization system for ankle injuries has been a top priority for us. We believe this unique and proprietary product addresses the complexities of this indication and mimics not only the dynamic environment, but also transitions the function of stabilization to best match the healing phases of the soft tissues. Approximately 20% of all ankle injuries require implants for soft tissue healing. As a result, we believe the R3ACT™ Stabilization System will be a nice complement to our entire ankle fracture portfolio.”

About Paragon 28, Inc.

Based in Englewood, CO., Paragon 28, is a leading medical device company exclusively focused on the foot and ankle orthopedic market and is dedicated to improving patient lives. From the onset, Paragon 28® has provided innovative orthopedic solutions, procedural approaches and instrumentation that cover a wide range of foot and ankle ailments including fracture fixation, hallux valgus (bunions), hammertoe, ankle, progressive collapsing foot deformity (PCFD) or flatfoot, charcot foot and orthobiologics. The company designs products with both the patient and surgeon in mind, with the goal of improving outcomes, reducing ailment recurrence and complication rates, and making the procedures simpler, consistent, and reproducible.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220419005422/en/

Investor Contact:

Gilmartin Group

Matt Bacso, CFA

matt.bacso@gilmartinir.com

Source: Paragon 28, Inc.

FAQ

What is the R3ACT™ Stabilization System launched by Paragon 28?

The R3ACT™ Stabilization System is a medical device designed for multi-stage soft tissue healing following syndesmotic ankle injuries.

What percentage of ankle injuries require implants according to Paragon 28?

Approximately 20% of all ankle injuries require implants for soft tissue healing.

How does the R3ACT™ Stabilization System benefit patients?

It mimics the dynamic environment and aids in the transition of stabilization functions to match the healing phases of soft tissues.

What market does Paragon 28 focus on?

Paragon 28 focuses exclusively on the foot and ankle orthopedic market.